Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02694744 · ClinicalTrials.gov registry record · Phase 4
Patiromer With or Without Food for the Treatment of Hyperkalemia
A Phase 4 study, sponsored by Relypsa.
- Completed
- Registry status
- Phase 4
- Development phase
- 114
- Enrollment target
NCT02694744 is a Phase 4 study that has completed, run by Relypsa. The registered enrollment target is 114 participants.
The verdict
NCT02694744, a Phase 4 study, has completed, sponsored by Relypsa.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high potassium in the blood).
Interventions
- DRUG patiromer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02694744
The ClinicalTrials.gov registry entry for NCT02694744 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Relypsa, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which patiromer is the first listed.
NCT02694744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02694744 about?
NCT02694744 is a clinical study titled "Patiromer With or Without Food for the Treatment of Hyperkalemia". The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high potassium in the blood).
What is the current status of trial NCT02694744?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2016-02. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02694744?
The interventions under investigation include: patiromer (DRUG).
Who is sponsoring clinical trial NCT02694744?
This trial is sponsored by Relypsa, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.